Genedrive plc (LSE:GDR) has announced changes to its board structure with the appointment of major shareholder David Nugent as a non-executive director. Nugent, who owns more than a quarter of the company’s issued share capital, recently participated as a cornerstone investor in Genedrive’s February equity fundraising.
The company said Nugent has agreed to waive his director’s fees until Genedrive achieves EBITDA profitability, reinforcing support for the business as it advances the commercial rollout of its point-of-care pharmacogenetic testing products in the UK and international markets.
The appointment comes as long-serving chairman Dr Ian Gilham and non-executive director Chris Yates prepare to step down from the board. Genedrive has launched a formal search process for a new independent chair alongside two additional independent non-executive directors as part of a broader governance refresh.
Leadership transition supports commercial growth plans
Dr Gilham described Nugent’s backing of the company’s funding strategy as an important factor in supporting Genedrive’s long-term development plans and characterised the board transition as a natural progression following his tenure since 2014.
Nugent said the company is in its strongest position for several years, highlighting the commercial potential of its recently launched testing products. He also stated that he intends to support the recruitment of additional independent board members while working closely with management to accelerate market adoption and overseas expansion.
Financial pressures continue despite improving technical signals
Genedrive’s outlook remains constrained by weak financial fundamentals, including substantial ongoing losses, continued cash burn and a declining equity base, although debt levels remain relatively low.
Technical indicators provide some support, with the shares trading above major moving averages and momentum readings remaining broadly neutral. However, valuation metrics remain under pressure due to negative earnings and the absence of dividend yield support.
More about Genedrive
Genedrive plc is a UK-based commercial-stage pharmacogenetics business focused on rapid point-of-care diagnostic assays designed to support safer and more effective prescribing decisions in emergency and acute healthcare settings. Its CE-IVD approved and NICE-recommended Genedrive CYP2C19 and MT-RNR1 ID tests are already being used within the NHS to support precision stroke treatment and reduce the risk of antibiotic-related hearing loss in newborn babies.
Leave a Reply